Rhythm Pharmaceuticals (RYTM) Preferred Stock Liabilities (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Preferred Stock Liabilities of $114.7 million for Q1 2026, down 20.42% year-over-year from $144.1 million in Q1 2025, and down 12.41% quarter-over-quarter from $131.0 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Preferred Stock Liabilities (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Preferred Stock Liabilities for 6 consecutive years, with $114.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Preferred Stock Liabilities fell 20.42% year-over-year to $114.7 million; the TTM figure through Mar 2026 stood at $114.7 million (down 20.42% YoY), while the FY2025 annual figure was $131.0 million, down 8.31% from the prior year.
- Preferred Stock Liabilities declined to $114.7 million in Q1 2026 per RYTM's latest filing, from $131.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $146.9 million in Q3 2025 and bottomed at $1.6 million in Q2 2022.
- Historically, Preferred Stock Liabilities has averaged $123.1 million across 4 years, with a median of $141.5 million in 2024.
- Annual changes were most pronounced in 2025 — Preferred Stock Liabilities rose 3.81% — and 2026, when it declined 20.42%.
- Rhythm Pharmaceuticals' Preferred Stock Liabilities stood at $1.6 million in 2022, then soared by 8882.39% to $142.8 million in 2024, then decreased by 8.31% to $131.0 million in 2025, then declined by 12.41% to $114.7 million in 2026.
- Business Quant data shows RYTM's Preferred Stock Liabilities at $114.7 million in Q1 2026, $131.0 million in Q4 2025, and $146.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 114.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114.32 Mn |
| Mar 31, 2026 | 114.71 Mn |
| Dec 31, 2025 | 130.96 Mn |
| Sep 30, 2025 | 146.87 Mn |
| Jun 30, 2025 | 145.49 Mn |
| Mar 31, 2025 | 144.14 Mn |
| Dec 31, 2024 | 142.82 Mn |
| Sep 30, 2024 | 141.48 Mn |
| Jun 30, 2024 | 140.15 Mn |
| Jun 30, 2022 | 1.59 Mn |
| Sep 30, 2017 | 80.95 Mn |
| Dec 31, 2016 | 40.00 Mn |